ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.
about
ALK Signaling and Target Therapy in Anaplastic Large Cell LymphomaAnaplastic lymphoma kinase: signalling in development and diseaseEuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytesSafety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphomaRomidepsin for the Treatment of Peripheral T-Cell LymphomaSarcomatoid variant of ALK- anaplastic large cell lymphoma involving multiple lymph nodes and both lungs with production of proinflammatory cytokines: report of a case and review of literatureThe aggressive peripheral T-cell lymphomas: 2013Peripheral T-cell and NK-cell lymphomas in the WHO classification: pearls and pitfallsCD30+ Lymphoproliferative Disorders of the Skin.Diagnostic, prognostic and therapeutic role of CD30 in lymphoma.T-cell lymphomas, a challenging disease: types, treatments, and future.Treatment of peripheral T-cell lymphoma: are we data driven or driving the data?Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study.Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma.Rare lymphoid malignancies of the breast: a report of two cases illustrating potential diagnostic pitfalls.The heterogeneous landscape of ALK negative ALCL.Research progresses in the pathogenesis of anaplastic large cell lymphoma.Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphomaUnderstanding rare adverse sequelae of breast implants: anaplastic large-cell lymphoma, late seromas, and double capsules.Cutaneous Anaplastic Large T-Cell Lymphoma with Invasion of the Central Nervous System: A Case Report.Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencingLong-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant.PAX5-positive T-cell anaplastic large cell lymphomas associated with extra copies of the PAX5 gene locusCombination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma.Diagnostic accuracy of a defined immunophenotypic and molecular genetic approach for peripheral T/NK-cell lymphomas. A North American PTCL study group project.Brentuximab vedotin in hodgkin lymphoma and anaplastic large cell lymphomaAutomatic lymphoma classification with sentence subgraph mining from pathology reports.ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes.Medical history, lifestyle, family history, and occupational risk factors for peripheral T-cell lymphomas: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.Prognostic markers in peripheral T-cell lymphomaBrentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I studyExtranodal anaplastic large cell lymphoma mimicking sarcoma: A report of an interesting case.Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas.Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas.Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients.ALK-driven tumors and targeted therapy: focus on crizotinibPediatric lymphomas and histiocytic disorders of childhoodClinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential.The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applicationsPhase I / II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma.
P2860
Q21129306-1F8A9439-9171-44CA-8041-796761964021Q24312329-55D405CD-5A4F-404F-8FD5-89E0487E6794Q24604581-C13877A0-DD32-4899-A08C-3F2512808FBBQ24633761-C8FC71E6-05B6-4864-93B7-0BD29041EA4DQ26785732-431815E2-13B1-4148-A717-40D5A7FA46BEQ26860515-43BF1806-716D-416A-8068-D7F7ED405D2FQ27003257-DEA073D8-E4E0-4674-AB72-B0328F745E7BQ27004241-51259C38-39CC-42B9-91C5-45E40C62385EQ30235097-7D30B629-DF9B-4EB3-8EDF-14F5B48E07FDQ30240160-E6FE4C31-A095-45C8-BFE3-CD6125F3EC5AQ30244553-BB8ADC73-F68F-479D-B0FB-51E99C0D4B09Q30613674-1806AD52-818F-460F-B97E-02A5F8178BB6Q33396356-7B5A97AB-2D6A-432D-9E95-3D0D998BE411Q33410081-B627070D-BE9C-4759-A3F5-7634A24C7D39Q33560745-DA73159B-FB15-4DBC-BA84-8145515386D0Q33567012-9E8406AB-CBE5-4C0A-BC23-21414D95035EQ33579708-FB173284-B625-489F-BF74-F1EE0E113D24Q33585243-5D945AF0-23A3-44DA-8838-92BA2A93F29DQ33617362-809FC08B-5FF5-4397-A14D-09B03D85F474Q33694257-1F1B6723-878B-4D8D-94D6-74CC6A491BBDQ33732485-89A61ECD-DC90-4EC2-A285-994B27F23C08Q33745878-7BA8B818-BC51-489E-A893-FF63AA06F5F5Q33766227-C1AA0643-3BFD-4600-9F6C-05AFA7FE36D9Q33817711-2CADC316-D9F5-4D50-A332-60311F8C92B9Q33856647-0D204458-0A00-4166-9250-21CE4893CB6CQ33885565-6C8BF056-035B-4554-B231-F07A295E7FD8Q34101867-2CFC14A3-69A3-4F42-8C57-E4547368DB2FQ34106853-6F50DA7E-0250-430E-AFDF-6CA075C63DBEQ34137956-751D40F3-A528-4259-8591-070F43F8C652Q34166857-6B68BC55-8ABC-41D8-8C27-1CEC7E767217Q34226010-A2F107E8-32FC-498C-B80A-C26697B43D80Q34272033-6D79D700-C7A5-40BA-8D37-37533A163584Q34362370-96F9C33C-972B-461C-8458-25BB67225D37Q34370320-88668985-CC4E-4861-9544-142449DAA41DQ34401878-814E1E67-8276-4823-B2B2-37CB123DFEB4Q34414378-1C9C0160-234A-4994-B258-1030BF4F53C9Q34605894-B2918965-7887-476F-AD2A-FD042801A2CEQ35021459-FBCB8240-2D98-412A-8436-F81CBDE05930Q35029409-6AE9C9D0-2F8C-4EFA-A4C4-AFF003ADC982Q35051886-F1E8729A-9DCE-4C7D-86AD-D66A7444C092
P2860
ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
ALK- anaplastic large-cell lym ...... heral T-Cell Lymphoma Project.
@ast
ALK- anaplastic large-cell lym ...... heral T-Cell Lymphoma Project.
@en
ALK- anaplastic large-cell lym ...... heral T-Cell Lymphoma Project.
@nl
type
label
ALK- anaplastic large-cell lym ...... heral T-Cell Lymphoma Project.
@ast
ALK- anaplastic large-cell lym ...... heral T-Cell Lymphoma Project.
@en
ALK- anaplastic large-cell lym ...... heral T-Cell Lymphoma Project.
@nl
prefLabel
ALK- anaplastic large-cell lym ...... heral T-Cell Lymphoma Project.
@ast
ALK- anaplastic large-cell lym ...... heral T-Cell Lymphoma Project.
@en
ALK- anaplastic large-cell lym ...... heral T-Cell Lymphoma Project.
@nl
P2093
P50
P1433
P1476
ALK- anaplastic large-cell lym ...... heral T-Cell Lymphoma Project.
@en
P2093
Elaine S Jaffe
International Peripheral T-Cell Lymphoma Project
Kerry J Savage
Lisa Rimsza
Mukesh Chhanabhai
Nancy Lee Harris
Stefano A Pileri
P304
P356
10.1182/BLOOD-2008-01-134270
P407
P577
2008-04-02T00:00:00Z